Oncomine Again Key To Prostate Cancer Discovery

Compendia Bioscience, Inc., the leading provider of cancer profiling data and analysis tools, announced the central role of their flagship product Oncomine(TM) in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer.Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number arrays coupled with analysis functions and a web application for data mining and visualization. Comprised of thousands of samples representing every major type of cancer, Oncomine exploits this data for therapeutic target discovery, validation, and prioritization. Compendia CEO Daniel R. Rhodes, Ph.D., in his continued role as a research investigator at the University of Michig...